Ipsen (Paris:IPN) today announced that the European Commission granted marketing authorisation for Increlex® (mecasermin) 10 mg/ml solution for injection in the European Union. The indication approved is for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor-1 deficiency (severe primary IGFD).
